Copyright: ©Author(s) 2026.
World J Gastroenterol. Sep 14, 2026; 32(34): 119605
Published online Sep 14, 2026. doi: 10.3748/wjg.119605
Published online Sep 14, 2026. doi: 10.3748/wjg.119605
Figure 4 Gavage with Cladosporium cladosporioides inhibited colonic inflammation and mast cell activation.
A: Mast cell tryptase expression based on western blot analysis of colonic mucosa; B: Quantification of tryptase protein levels normalized to β-actin levels; C: Mast cell tryptase mRNA expression based on reverse transcription-quantitative polymerase chain reaction of colonic mucosa. One outlier identified and removed with Turkey outlier analysis in saline + Cladosporium cladosporioides group; D: Cytokine mRNA expression based on reverse transcription-quantitative polymerase chain reaction of colonic mucosa; E: Serum mast cell tryptase detected using enzyme-linked immunosorbent assay; F: Cytokine expression in colonic mucosa detected using enzyme-linked immunosorbent assay. Data are presented as the mean ± SD. Two-way ANOVA (n = 7). aP < 0.05, bP < 0.01, cP < 0.001. TNBS: Trinitrobenzene sulfonic acid; MCP: Monocyte chemoattractant protein; TNF: Tumor necrosis factor; IL: Interleukin.
- Citation: Guo CL, Zhang SQ, Zheng HN, Chi Y, Wang HH. Cladosporium cladosporioides ameliorates visceral hypersensitivity in irritable bowel syndrome-like mice by inhibiting dectin-1 signaling and mast cell activation. World J Gastroenterol 2026; 32(34): 119605
- URL: https://www.wjgnet.com/1007-9327/full/v32/i34/119605.htm
- DOI: https://dx.doi.org/10.3748/wjg.119605